Novartis AG’s exit from India underscores a broader trend of Big Pharma retreating amid strict patent safeguards and limited R&D incentives, highlighting how India’s pro-generic policy has strengthened domestic drugmakers.
Popular Posts
-
The Allahabad High Court has observed that there can be no room for discrimination or high-handedness when investigating agencies instruct ...
-
Bengaluru-based private space technology company GalaxEye's upcoming satellite mission, Mission Drishti, will feature NVIDIA Jetson Ori...
